Physician profile
Kaitlyn Yim
NPI 1174075303
$13,611.87
in general payments reported to CMS, 2019-2025
24 companies · $8,603 in 2025
The $8,603 reported for 2025 was more than what 94% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $842 · 2023: $1,574 · 2024: $2,354 · 2025: $8,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,200 · Food and Beverage: $6,141 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,200.00 |
| Food and Beverage | $6,141.28 |
| Education | $189.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $6,821.76 | 2022-2025 | Aklief, Nemluvio, Oracea |
| Abbvie INC. | $2,145.90 | 2022-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $757.08 | 2021-2025 | |
| Dermavant Sciences, INC. | $595.81 | 2023-2024 | Vtama |
| Ucb, INC. | $585.31 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $565.16 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $315.92 | 2023-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $277.10 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $258.41 | 2022-2024 | Winlevi |
| Arcutis Biotherapeutics, INC. | $205.75 | 2023-2025 | Zoryve |
| Organon LLC | $192.02 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.76 | 2022-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $153.84 | 2023-2025 | |
| Lilly USA, LLC | $104.26 | 2024-2025 | Taltz, Ebglyss |
| Pfizer INC. | $99.85 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $63.83 | 2025 | |
| Leo Pharma INC. | $54.44 | 2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $50.43 | 2024-2025 | |
| Almirall LLC | $48.14 | 2023-2024 | Klisyri, Seysara |
| Janssen Scientific Affairs, LLC | $35.44 | 2025 | Tremfya |
| Biocodex, INC. | $30.53 | 2025 | |
| Botanix Sb INC | $28.08 | 2025 | Sofdra |
| Amgen INC. | $23.56 | 2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Yim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.